DnB Asset Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.03M Sell
30,942
-1,249
-4% -$259K 0.02% 443
2026
Q1
$7.23M Buy
32,191
+1,951
+6% +$486K 0.03% 364
2025
Q4
$7.28M Buy
30,240
+1,664
+6% +$426K 0.03% 359
2025
Q3
$7.82M Buy
28,576
+959
+3% +$262K 0.03% 340
2025
Q2
$7.13M Buy
27,617
+996
+4% +$238K 0.03% 323
2025
Q1
$5.96M Sell
26,621
-81
-0.3% -$18.9K 0.03% 346
2024
Q4
$6.11M Buy
26,702
+1,729
+7% +$416K 0.03% 350
2024
Q3
$6.1M Buy
24,973
+924
+4% +$206K 0.03% 356
2024
Q2
$4.6M Buy
24,049
+938
+4% +$190K 0.02% 365
2024
Q1
$4.58M Sell
23,111
-2,919
-11% -$535K 0.02% 367
2023
Q4
$4.48M Sell
26,030
-203
-0.8% -$31.2K 0.02% 388
2023
Q3
$3.88M Buy
26,233
+383
+1% +$69.3K 0.02% 402
2023
Q2
$5.65M Sell
25,850
-383
-1% -$85.4K 0.03% 336
2023
Q1
$5.74M Buy
26,233
+1,059
+4% +$230K 0.04% 335
2022
Q4
$5.24M Sell
25,174
-303
-1% -$66.6K 0.04% 341
2022
Q3
$5.56M Sell
25,477
-535
-2% -$122K 0.04% 314
2022
Q2
$5.45M Buy
26,012
+642
+3% +$137K 0.04% 315
2022
Q1
$6.15M Buy
25,370
+1,662
+7% +$402K 0.04% 328
2021
Q4
$6.18M Buy
23,708
+730
+3% +$189K 0.04% 327
2021
Q3
$6.06M Buy
22,978
+350
+2% +$95.7K 0.04% 311
2021
Q2
$5.58M Buy
22,628
+774
+4% +$163K 0.04% 349
2021
Q1
$4.24M Buy
21,854
+2,105
+11% +$422K 0.03% 367
2020
Q4
$4.2M Buy
19,749
+1,343
+7% +$268K 0.04% 304
2020
Q3
$3.16M Buy
18,406
+712
+4% +$131K 0.03% 306
2020
Q2
$3.4M Buy
17,694
+2,321
+15% +$380K 0.04% 273
2020
Q1
$2.26M Sell
15,373
-1,106
-7% -$176K 0.03% 309
2019
Q4
$2.55M Buy
16,479
+1,823
+12% +$263K 0.03% 401
2019
Q3
$1.98M Buy
14,656
+807
+6% +$106K 0.02% 420
2019
Q2
$1.69M Sell
13,849
-924
-6% -$102K 0.02% 444
2019
Q1
$1.54M Sell
14,773
-5,154
-26% -$532K 0.02% 472
2018
Q4
$2.27M Buy
19,927
+1,882
+10% +$202K 0.03% 351
2018
Q3
$2.08M Buy
18,045
+2,745
+18% +$301K 0.02% 396
2018
Q2
$1.58M Buy
15,300
+800
+6% +$80.9K 0.02% 441
2018
Q1
$1.43M Buy
14,500
+1,600
+12% +$151K 0.02% 450
2017
Q4
$1.09M Hold
12,900
0.01% 487
2017
Q3
$993K Hold
12,900
0.01% 475
2017
Q2
$1M Sell
12,900
-600
-4% -$42.9K 0.01% 456
2017
Q1
$972K Buy
13,500
+3,000
+29% +$207K 0.02% 459
2016
Q4
$652K Buy
10,500
+100
+1% +$6.13K 0.01% 475
2016
Q3
$674K Buy
10,400
+400
+4% +$26.6K 0.01% 444
2016
Q2
$632K Hold
10,000
0.01% 436
2016
Q1
$578K Sell
10,000
-7,300
-42% -$413K 0.01% 445
2015
Q4
$929K Sell
17,300
-9,500
-35% -$535K 0.02% 329
2015
Q3
$1.37M Buy
26,800
+13,600
+103% +$732K 0.03% 265
2015
Q2
$744K Sell
13,200
-900
-6% -$56.8K 0.02% 370
2015
Q1
$1.01M Sell
14,100
-25,300
-64% -$1.64M 0.02% 346
2014
Q4
$2.21M Buy
+39,400
New +$2.06M 0.05% 216

Other funds holding RMD

DnB Asset Management's RMD Position: Q2 2026 in Review

DnB Asset Management reduced its ResMed (RMD) stake by 3.9% in Q2 2026, selling an estimated $259K and leaving 30,942 shares worth $6.03M. The position accounts for 0.02% of the portfolio, ranked #443.

DnB Asset Management first reported a position in RMD in Q4 2014 and has held it in 47 quarters since. The position peaked at $7.82M in Q3 2025. 575 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • DnB Asset Management held 30,942 shares of ResMed worth $6.03M as of Q2 2026.
  • DnB Asset Management sold 1,249 ResMed shares in Q2 2026, an estimated $259K.
  • ResMed made up 0.02% of DnB Asset Management's portfolio in Q2 2026, its #443 holding.
  • DnB Asset Management first reported a position in ResMed in Q4 2014 and has held it in 47 quarters since.
  • DnB Asset Management's ResMed position peaked at $7.82M in Q3 2025.
  • 575 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.